Given the documented association of the IL-36 pathway with systemic lupus erythematosus (SLE), reciprocal regulation, and the synergistic action between IL-17 and IL-36 in inflammation and fibrosis (Figure 2), we discuss the rationale for co-blockading IL-17 and IL-36 pathways in lupus nephritis. Here, IL17A is linked to systemic lupus erythematosus.